anti-CD235a antibody product blogThe CD235a n/a (Catalog #MBS530610) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The CD235a antibody (FITC) reacts with Human CD235a and may cross-react with other species as described in the data sheet. MyBioSource\'s CD235a can be used in a range of immunoassay formats including, but not limited to, Flow Cytometry (FC/FACS), Immunofluorescence (IF). Researchers should empirically determine the suitability of the CD235a n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Mouse monoclonal CD235a antibody (FITC).
Biological Significance: CD235a is a major sialoglycoprotein of the human erythrocyte membrane which bear the antigenic determinants for the MN and Ss blood groups. In addition to the M or N and S or s antigens, that commonly occur in all populations, about 40 related variant phenotypes have been identified. These variants include all the variants of the Miltenberger complex and several isoforms of Sta; also, Dantu, Sat, He, Mg, and deletion variants Ena, S-s-U- and Mk. Most of the variants are the result of gene recombinations between GYPA and GYPB. Tag/Conjugate: FITC
Immunogen: CD235a antibody (FITC) was raised in mouse using human erythrocytes as the immunogen. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CD235a are readily searchable from our website. Different antibodies against the same target such as CD235a may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.